Logo image of CUE

CUE BIOPHARMA INC (CUE) Stock Fundamental Analysis

NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD

1.32  -0.05 (-3.65%)

Fundamental Rating

2

Taking everything into account, CUE scores 2 out of 10 in our fundamental rating. CUE was compared to 572 industry peers in the Biotechnology industry. CUE may be in some trouble as it scores bad on both profitability and health. CUE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CUE had negative earnings in the past year.
CUE had a negative operating cash flow in the past year.
CUE had negative earnings in each of the past 5 years.
CUE had a negative operating cash flow in each of the past 5 years.
CUE Yearly Net Income VS EBIT VS OCF VS FCFCUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of CUE (-99.56%) is worse than 75.84% of its industry peers.
Looking at the Return On Equity, with a value of -175.87%, CUE is doing worse than 67.67% of the companies in the same industry.
Industry RankSector Rank
ROA -99.56%
ROE -175.87%
ROIC N/A
ROA(3y)-64.49%
ROA(5y)-57.94%
ROE(3y)-94.98%
ROE(5y)-81.79%
ROIC(3y)N/A
ROIC(5y)N/A
CUE Yearly ROA, ROE, ROICCUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

CUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CUE Yearly Profit, Operating, Gross MarginsCUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
CUE has more shares outstanding than it did 1 year ago.
CUE has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CUE has a worse debt to assets ratio.
CUE Yearly Shares OutstandingCUE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CUE Yearly Total Debt VS Total AssetsCUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

CUE has an Altman-Z score of -10.31. This is a bad value and indicates that CUE is not financially healthy and even has some risk of bankruptcy.
CUE's Altman-Z score of -10.31 is on the low side compared to the rest of the industry. CUE is outperformed by 74.25% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that CUE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, CUE is doing worse than 63.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -10.31
ROIC/WACCN/A
WACC9.76%
CUE Yearly LT Debt VS Equity VS FCFCUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 2.22 indicates that CUE has no problem at all paying its short term obligations.
With a Current ratio value of 2.22, CUE is not doing good in the industry: 74.60% of the companies in the same industry are doing better.
CUE has a Quick Ratio of 2.22. This indicates that CUE is financially healthy and has no problem in meeting its short term obligations.
CUE has a worse Quick ratio (2.22) than 73.18% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.22
CUE Yearly Current Assets VS Current LiabilitesCUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.17% over the past year.
The Revenue has grown by 149.53% in the past year. This is a very strong growth!
The Revenue has been growing by 36.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
Revenue 1Y (TTM)149.53%
Revenue growth 3Y20.34%
Revenue growth 5Y36.94%
Sales Q2Q%58.86%

3.2 Future

Based on estimates for the next years, CUE will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.35% on average per year.
The Revenue is expected to grow by 51.67% on average over the next years. This is a very strong growth
EPS Next Y30.66%
EPS Next 2Y22.46%
EPS Next 3Y16.45%
EPS Next 5Y9.35%
Revenue Next Year94.59%
Revenue Next 2Y46.98%
Revenue Next 3Y57.85%
Revenue Next 5Y51.67%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CUE Yearly Revenue VS EstimatesCUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CUE Yearly EPS VS EstimatesCUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
Also next year CUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUE Price Earnings VS Forward Price EarningsCUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUE Per share dataCUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

CUE's earnings are expected to grow with 16.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.46%
EPS Next 3Y16.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUE BIOPHARMA INC

NASDAQ:CUE (2/21/2025, 8:11:19 PM)

1.32

-0.05 (-3.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-12 2025-03-12/amc
Inst Owners18.55%
Inst Owner Change-16.27%
Ins Owners0.55%
Ins Owner Change1.34%
Market Cap83.62M
Analysts86.67
Price Target3.67 (178.03%)
Short Float %1.74%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.42%
Min EPS beat(2)12.56%
Max EPS beat(2)30.27%
EPS beat(4)3
Avg EPS beat(4)12.94%
Min EPS beat(4)-3.28%
Max EPS beat(4)30.27%
EPS beat(8)6
Avg EPS beat(8)8.49%
EPS beat(12)9
Avg EPS beat(12)11.2%
EPS beat(16)10
Avg EPS beat(16)8.91%
Revenue beat(2)2
Avg Revenue beat(2)110.74%
Min Revenue beat(2)104.15%
Max Revenue beat(2)117.33%
Revenue beat(4)4
Avg Revenue beat(4)69.17%
Min Revenue beat(4)15.03%
Max Revenue beat(4)117.33%
Revenue beat(8)7
Avg Revenue beat(8)45.46%
Revenue beat(12)8
Avg Revenue beat(12)24.15%
Revenue beat(16)11
Avg Revenue beat(16)35.72%
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)57.84%
EPS NY rev (1m)0%
EPS NY rev (3m)5.14%
Revenue NQ rev (1m)7.64%
Revenue NQ rev (3m)70.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.77
P/FCF N/A
P/OCF N/A
P/B 3.3
P/tB 3.3
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.15
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.56%
ROE -175.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.49%
ROA(5y)-57.94%
ROE(3y)-94.98%
ROE(5y)-81.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.42%
Cap/Sales 0.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.22
Altman-Z -10.31
F-Score4
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)30.23%
Cap/Depr(5y)30.7%
Cap/Sales(3y)6.56%
Cap/Sales(5y)8.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
EPS Next Y30.66%
EPS Next 2Y22.46%
EPS Next 3Y16.45%
EPS Next 5Y9.35%
Revenue 1Y (TTM)149.53%
Revenue growth 3Y20.34%
Revenue growth 5Y36.94%
Sales Q2Q%58.86%
Revenue Next Year94.59%
Revenue Next 2Y46.98%
Revenue Next 3Y57.85%
Revenue Next 5Y51.67%
EBIT growth 1Y14.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.77%
OCF growth 3YN/A
OCF growth 5YN/A